Introduction {#sec0001}
============

Preliminary reports suggest that patients with Coronavirus Disease 2019 (COVID-19) are at high risk of hematologic complications, including disseminated intravascular coagulation (DIC).[@bib0001] ^--^ [@bib0003] Patients with COVID-19 may exhibit hemostatic abnormalities with the potential to precipitate both hemorrhagic and thromboembolic events, including mild thrombocytopenia, prolongation of both prothrombin time and international normalized ratio, and shortened activated partial thromboplastin time, and both ischemic stroke and intracerebral hemorrhage have been described in infected patients.[@bib0004], [@bib0005], [@bib0006] ^--^ [@bib0007] However, limited evidence exists in the literature for management of acute stroke in COVID-19 given the concomitant risk of hemorrhage, and recommendations are based on consensus only.[@bib0008]

The safety and efficacy of intravenous tissue plasminogen activator (IV tPA) for acute ischemic stroke in patients with COVID-19 remain unknown.[@bib0001] We present the outcomes of a multicenter series of patients with confirmed COVID-19 infection who were treated with IV tPA for suspected acute ischemic stroke.

Methods {#sec0002}
=======

All patients with COVID-19 who received IV tPA for acute neurological deficits between March 1, 2020 and July 1, 2020 were identified at the participating hospitals by the corresponding stroke provider at each institution. The study protocol was approved or given exemptions by local institutional review boards. All patients included were diagnosed with COVID-19 by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR from a nasopharyngeal swab, presented with acute neurological deficits (\< 24 h), received IV tPA per acute ischemic stroke American Heart Association guidelines, and underwent brain and intracranial vessel imaging.[@bib0009] Laboratory values were obtained within 24 hours of admission ([Table 1](#tbl0001){ref-type="table"} ). Stroke mechanism was primarily defined using the TOAST classification, with some strokes classified as embolic strokes of undetermined source (ESUS). [@bib0010] ^,^ [@bib0011] Table 1Clinical characteristics of patients with acute neurological deficits and COVID-19Table 1**VariablePatient 1Patient 2Patient 3Patient 4Patient 5Patient 6Patient 7Patient 8Patient 9Patient 10Age (years)**73475572249374845775**Sex**MaleFemaleMaleMaleMaleFemaleMaleFemaleMaleMale**Medical history and stroke risk factors**Hypertension Dyslipidemia SmokingHypertension DiabetesHypertension DyslipidemiaCADDiabetes Dyslipidemia Obesity Cocaine useAtrial fibrillation CAD HypertensionStroke CAD Hypertension CardiomyopathyStroke CAD Hypertension DyslipidemiaCAD Hypertension Cocaine useCAD Hypertension**Medications**NoneMetforminOlanzapine Valproic acidNoneNoneAspirin Clopidogrel CarvedilolAspirin Atorvastatin Lisinopril MetoprololClopidogrel Hydrochlorothiazide Losartan AtenololNoneAmlodipine Clonidine Metformin Metoprolol Simvastatin**NIHSS score at admission**781726181621131024**NIHSS score at 24h**90423025 (intubated)N/A7222**NIHSS score at last follow up**8 (day 11)0 (day 3)2 (day 12)16 (day 2)0 (day 1)N/A (improvement noted)0 (day 41)7 (day 4)0 (day 12)19 (day 2)**Outcome status**Discharged to rehabilitation facilityDischarged homeDischarged to long term acute facilityDischarged homeDischarged homeDischarged to outpatient hospice.Discharged homeDischarged home (baseline neurological exam)Discharged to rehabilitation facilityN/A**Time to presentation**60 minutes60 minutes100 minutes113 minutes120 minutes150 minutes45 minutes540 minutes60 minutes102 minutes**LKW to needle**160 minutes100 minutes150 minutes184 minutes165 minutes180 minutes120 minutes600 minutes115 minutes225 minutes**Complications**NoneNoneNoneAsymptomatic Petechial Hemorrhagic TransformationNoneNoneNoneNoneNoneNone**Signs and symptoms of stroke**Right facial weakness Right hemiparesis Right sensory lossAphasia Right facial weakness Right hemiparesis Right hemisensory lossDysarthria Right hemiparesis, Altered mental statusAphasia Right hemiparesisLeft hemiplegia Left hemisensory loss Left Homonymous Hemianopia DysarthriaLeft-sided weakness Dysarthria NeglectAphasia Right face weakness Right hemiplegia Right hemisensory lossRight gaze deviation Right face weakness Right hemiparesis Right hemisensory lossVertigo Dysarthria Nausea Unsteady gait Left hemiparesisAphasia Right Hemiparesis Right hemianopia**Imaging**CT, CTA, MRICT, CTA, MRI, DSACT, CTA, MRICT, CTACT, CTA, CTPCT, CTA, DSACT, CTA, DSACT, CTA CT PerfusionCT, CTA, MRICT, CTA, MRI**Imaging Results**CTA: unremarkable MRI: Restricted diffusion in left internal capsule, left parietal and right frontal lobesCTA: Left middle cerebral artery occlusion at M2 segment DSA: No evidence of LVO MRI: unremarkableCTA: Left middle cerebral artery stenosis at M1 segment MRI: unremarkableCTA: Left middle cerebral artery occlusion at distal M1 segmentCTA: UnremarkableCT: Right frontotemporal hypodensity CTA: Right middle cerebral artery occlusion at distal M1 segment DSA: TICI IIICT: Old left frontal and right parietal hypodensities CTA: Left middle cerebral artery occlusion at M1 segment DSA: TICI IIICTA: Unremarkable MRI: Restricted diffusion in left ventral ponsCTA: Left vertebral occlusion /stenosis MRI: Restricted diffusion in both cerebellar hemispheresCTA: Left middle cerebral artery occlusion at M2 segment L ICA thrombus MRI: Restricted diffusion in in left insula and left frontal and temporal lobes**Treatment for stroke**tPAtPAtPAtPAtPAtPA and Thrombectomy TICI Score IIItPA and Thrombectomy TICI Score IIItPAtPAtPA**Covid-19 symptoms**Fever Cough DyspneaCoughFever EncephalopathyCoughFever DyspneaFever DyspneaCough Dyspnea MalaiseCough DyspneaDyspneaCough**White cell count (1000/per mm3)**8.56.710.19.98.25.46.0110.210.410.2**Absolute Lymphocyte count (1000/per mm3)**5.21.72.40.73.10.71.41.41.51.21**Platelet count (1000/per mm3)**213291209186142214173402207280**Prothrombin time (sec)**13.315.811.213.514.110.814.812.613.110.5**Activated partial thromboplastin time (sec)**31302831.82628.832.527.631.225.5**Fibrinogen (mg/dl)**463101206266217N/A61315456410**D-dimer (ng/ml)**18922668955449810N/AN/A148313415501**Ferritin (ng/ml)**123118363362.207552N/A674177.5229**Transthoracic echocardiogram**No LAE No RWA No cardiac shunt No cardiac thrombusNo LAE No intracardiac thrombus or vegetation. No RWAN/AN/ANo LAE No RWA No cardiac shunt No cardiac thrombusLAEN/AN/ANo LAE No RWA No cardiac shunt No cardiac thrombusNo cardiac thrombus**Atrial Fibrillation**Not detectedNot detectedNot detectedPresentNot detectedPresentNot detectedNot detectedNot detectedNot detected**Stroke mechanism**ESUSTIA/Aborted StrokeTIA/Aborted StrokeCardioembolic (atrial fibrillation)Cocaine Use TIA/Aborted StrokeCardioembolic (atrial fibrillation)CryptogenicSVDLarge artery atherosclerosis Cocaine useLarge artery atherosclerosisTable 1ContinuationTable 2**VariablePatient 11Patient 12Patient 13Age (years)**535841**Sex**FemaleMaleMale**Medical history and stroke risk factors**NoneNoneHypertension Diabetes Heart Failure Morbid Obesity**Medications**NoneNoneLosartan Metformin Glipizide Furosemide**NIHSS score at admission**348**NIHSS score at 24h**1321 (intubated)**NIHSS score at last follow up**0 (day 3)3 (day 2)19 (intubated day 24)**Outcome status**HomeHomen/a**Time to presentation**133 minutes122 minutes85 minutes**LKW to needle**167 minutes280 minutes154 minutes**Complications**NoneNoneNone**Signs and symptoms of stroke**Aphasia Right sensory lossAphasia Left HemianopiaDysarthria Right hemiparesis**Imaging**CT, CTA, CTP, DSACT, CTACT, CTA**Imaging Results**CTA: Left Middle Cerebral artery occlusion at M1 segment DSA: TICI IIICTA: Right middle cerebral artery occlusion at M2 segmentCT: Left temporoparietal and occipital hypodensities. Right parietal hypodensity. CTA: Unremarkable**Treatment for stroke**tPA Thrombectomy TICI IIItPAtPA**Covid-19 symptoms**Fever DyspneaCough DyspneaNone**White cell count (1000/per mm3)**7.26.87.7**Absolute Lymphocyte count (1000/per mm3)**2.11.03.5**Platelet count (1000/per mm3)**210464223**Prothrombin time (sec)**12.813.514.2**Activated partial thromboplastin time (sec)**302925pt**Fibrinogen (mg/dl)**265132266**D-dimer (ng/ml)**10448816.554**Ferritin (ng/ml)**65446740**Transthoracic echocardiogram**No LAE No cardiac thrombusNo LAE No cardiac thrombusCardiomyopathy EF 10% No cardiac thrombus**Atrial Fibrillation**Not detectedNot detectedAtrial tachycardias**Stroke mechanism**ESUSESUSCardioembolic[^2][^3][^4][^5][^6][^7][^8][^9][^10][^11][^12][^13][^14][^15][^16][^17][^18][^19][^20][^21][^22][^23][^24][^25][^26][^27]

Results {#sec0003}
=======

Patient characteristics {#sec0004}
-----------------------

A total of 13 patients were identified at 9 centers. Mean age was 62 (±9.8) years, and 9 (69.2%) were male ([Table 1](#tbl0001){ref-type="table"}). Median NIH stroke scale (NIHSS) score on admission was 14.5 (range 3--26). Eleven patients were treated within the standard window (4.5 h) with mean elapsed time between last known well and IV tPA administration of 155.4 (±24.2) min. One patient was treated with IV tPA in an extended window based on MRI/CT perfusion findings (600 min). One patient had IV tPA administered beyond the standard window based on clinical decision making with the patient (280 min).

CT angiography revealed large vessel occlusion (LVO) in 8 cases (61.5%) and MRI brain confirmed acute ischemic stroke in 4 cases (30.7%). Cerebral digital subtraction angiogram was performed in 4 (30.7%) patients. Three underwent thrombectomy, achieving thrombolysis in cerebral infarction (TICI) 3 reperfusion without complications, while one patient was found to have patent large vessels after IV tPA administration. The other four patients with LVO were not considered for thrombectomy due to unfavorable anatomy with proximal vessel stenosis or had intact collateral circulation with blood flow reconstitution distal to the occlusion site.

Stroke mechanisms included cardioembolic (3 patients), large artery atherosclerosis (2 patients), small vessel disease (1 patient), ESUS (3 patients) or cryptogenic with incomplete investigation (1 patient). Three patients were determined to have transient ischemic attacks (TIAs) or aborted strokes.

Systemic symptoms of COVID-19 were present in all patients, including fever (5 patients), cough (7 patients), and dyspnea (8 patients). Two out of 12 (16.6%) patients with fibrinogen levels tested had elevated fibrinogen levels on admission (mean 262.2 ± 87.5 mg/dl), and 7 out of 11 (63.6%) patients with D-dimer levels tested had an elevated D-dimer level (mean 4284.6 ±3368.9 ng/ml).

Safety and efficacy of IV tPA {#sec0005}
-----------------------------

No patients had symptomatic systemic or intracranial hemorrhage. One patient developed asymptomatic petechial hemorrhage in the area of infarction noted on routine follow-up imaging at 24 h. Median NIHSS score for patients with stroke at follow-up was 7.5 (range 0--25), and 8 (61.5%) patients had an improvement in their NIHSS score of 4 points or more. All patients survived to hospital discharge however one elderly patient was discharged to hospice because of severe respiratory symptoms.

Discussion {#sec0006}
==========

We describe a series of patients with COVID-19 who presented from the community and received IV tPA for acute ischemic stroke. In our series, intravenous thrombolysis was not associated with symptomatic complications, and the majority of patients had clinical improvement at follow-up.

Preliminary reports found a 1% incidence of stroke among hospitalized patients with COVID-19.[@bib0004] ^,^ [@bib0012] More recently, acute ischemic strokes have been noted in the early stages of illness, and LVO has been reported as the presenting symptom of COVID-19.[@bib0001] ^,^ [@bib0013] ^,^ [@bib0014] Patients with COVID-19 can also present with delirium, meningoencephalitis, and fever, which may be considered stroke mimics, posing a challenge in the evaluation for thrombolysis eligibility. [@bib0006] ^,^ [@bib0012] In 2 case series of LVO in patients with COVID-19, 45% of patients had encephalopathy at admission, suggesting that reduced level of consciousness could be a common presenting symptom in patients with COVID-19-associated stroke.[@bib0001] ^,^ [@bib0013] In our series, 61.5% patients had large vessel occlusion, but only 7% developed encephalopathy. Of note, although the Wuhan findings suggested that stroke was more common among critically ill patients, the patients in our series presented from the community with mild viral illness.[@bib0004] Preliminary reports also suggest more severe illness in male patients with COVID-19, an observation that may be reflected in the male predominance of our cohort.

Growing evidence suggests SARS-CoV-2 infection is associated with a pro-thrombotic state. This process is mediated by an inflammatory cascade that leads to elevated D-dimer and fibrinogen levels, low anti-thrombin III levels and pulmonary congestion with microvascular thromboses, especially in critically ill patients.[@bib0002] A clot waveform analysis study in patients with COVID-19 demonstrated that hypercoagulability preceded or coincided with severe illness.[@bib0015] Anti-phospholipid antibodies have been detected in some COVID-19 patients with thromboembolic events, including those with LVOs and strokes.[@bib0013] ^,^ [@bib0016] Our study shows a wide distribution of stroke etiologies, suggesting that COVID-19 may increase the risk for stroke through a variety of mechanisms, including those seen in other viral disorders.[@bib0017] Further studies are required to elucidate stroke etiology and any causal relationship between SARS-CoV-2 infection and stroke.

IV tPA has been used anecdotally in COVID-19 to treat acute respiratory distress syndrome, but no published data exist specifically on the safety of IV tPA for acute ischemic stroke treatment.[@bib0002] COVID-19 may also increase the risk of systemic or cerebral hemorrhagic complications, and has also been reported in association with acute hemorrhagic necrotizing encephalopathy.[@bib0018] Our series suggests that symptomatic hemorrhagic complications with IV tPA in patients with COVID-19 are infrequent and lower than the rate of complications in the general population (between 2% and 3.3%), reiterating a pro-coagulable state rather than a bleeding disorder.[@bib0019] ^,^ [@bib0020] Larger studies correlating outcomes post-thrombolysis with hemostatic measures such as d-dimer, fibrinogen levels, and thromboelastography are needed to better understand which patients are most likely to safely benefit from IV tPA administration.

Post-mortem studies have found additional evidence of fibrin-rich thrombi in patients with COVID-19, raising concern that IV tPA may be of limited benefit in this patient population in the setting of prior studies demonstrating a lower efficacy of tPA thrombolysis in thrombi with high fibrin content compared with erythrocyte-rich emboli.[@bib0021] ^,^ [@bib0022] However, the majority of included patients had an NIHSS score improvement of 4 or more points and were discharged home, suggesting that IV tPA is efficacious in these patients. Given the small number of patients in our series, our observations should be taken with caution. The majority of patients in the study had moderate to severe strokes (median NIHSS 14.5) and presented from the community. Therefore, our results may not be generalizable to those with mild strokes or who are critically ill.

In spite of the uncertain hematologic effects of COVID-19, our findings suggest that IV tPA may be used safely in acute ischemic stroke patients with COVID-19 and is associated with improved outcomes. Larger studies are needed to better understand safety and efficacy in this patient population.
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[^2]: CT: computerized tomography

[^3]: CTA: computed tomography angiography

[^4]: CTP: CT perfusion

[^5]: CAD: coronary artery disease

[^6]: CMO: comfort measures only

[^7]: DSA: Digital subtraction angiography

[^8]: ESUS: Embolic stroke of undetermined source

[^9]: LA: Left atrium

[^10]: LAE: left atrial enlargement.

[^11]: LKW: Last known well

[^12]: LVO: Large vessel occlusion

[^13]: N/A: Not available.

[^14]: NIHSS: National Institutes of Health stroke scale

[^15]: RWA: regional wall abnormality

[^16]: SVD: Small vessel disease

[^17]: TIA: Transient ischemic attack

[^18]: TICI: Thrombolysis in cerebral infarction

[^19]: **Reference ranges:**

[^20]: White blood count: 4.500 to 11.000 per cubic millimeter

[^21]: Absolute lymphocytes: 1.000 to 4.800 per cubic millimeter

[^22]: Platelet count: 150.000 to 450.000 per cubic millimeter

[^23]: Prothrombin time: 12.3 to 14.9 seconds

[^24]: Activated partial-thromboplastin time: 25.4 to 34.9 seconds

[^25]: Fibrinogen: 175 to 450 mg per deciliter;

[^26]: D-dimer: 0 to 500 ng per milliliter

[^27]: Ferritin: 30 to 400 ng per milliliter
